PET with florbetapir achieves good image quality
03.15.12
Publication: Wayne Forrest By:
A study in the March issue of the Journal of Nuclear Medicineprovides more evidence that the radiotracer florbetapir can be a “robust imaging tool.” It appears well-suited as a biomarker to detect characteristics of Alzheimer’s disease and someday could possibly guide treatment of individuals with the disease.
Medical Imaging Community Rallies Against Device Tax
MITA and its industry partners, including AdvaMed and MDMA, are calling on Congress to pass bipartisan legislation that repeals the medical device tax in a new ad campaign. Learn More
MITA Urges Congress to Reject Reimbursement Cuts
MITA calls on policymakers to protect access to life saving medical imaging technologies. Learn More
Why I Joined MITA – Navidea Biopharmaceuticals
Hear from Thomas Tulip, Executive Vice President and Chief Business Officer of Navidea Biopharmaceuticals, on why his organization joined MITA.
